Scholar Rock Holding (SRRK) Liabilities and Shareholders Equity (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Liabilities and Shareholders Equity of $535.3 million for Q1 2026, up 31.33% year-over-year from $407.6 million in Q1 2025, and up 32.4% quarter-over-quarter from $404.3 million in Q4 2025.
Scholar Rock Holding (SRRK) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $535.3 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 31.33% year-over-year to $535.3 million; the TTM figure through Mar 2026 stood at $1.7 billion (up 31.26% YoY), while the FY2025 annual figure was $404.3 million, down 14.88% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $535.3 million, up from $404.3 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $535.3 million in Q1 2026, with the low at $179.1 million in Q3 2024.
- The 5-year median for Liabilities and Shareholders Equity is $340.0 million (2025), against an average of $343.9 million.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity slumped 35.77% in 2023, then jumped 129.84% in 2025.
- Scholar Rock Holding's Liabilities and Shareholders Equity stood at $358.2 million in 2022, then decreased by 13.16% to $311.0 million in 2023, then soared by 52.69% to $474.9 million in 2024, then decreased by 14.88% to $404.3 million in 2025, then jumped by 32.4% to $535.3 million in 2026.
- Business Quant data shows SRRK's Liabilities and Shareholders Equity at $535.3 million in Q1 2026, $404.3 million in Q4 2025, and $411.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | 523.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 523.54 Mn |
| Mar 31, 2026 | 535.25 Mn |
| Dec 31, 2025 | 404.27 Mn |
| Sep 30, 2025 | 411.72 Mn |
| Jun 30, 2025 | 340.05 Mn |
| Mar 31, 2025 | 407.55 Mn |
| Dec 31, 2024 | 474.92 Mn |
| Sep 30, 2024 | 179.13 Mn |
| Jun 30, 2024 | 226.87 Mn |
| Mar 31, 2024 | 267.29 Mn |
| Dec 31, 2023 | 311.04 Mn |
| Sep 30, 2023 | 250.69 Mn |
| Jun 30, 2023 | 284.90 Mn |
| Mar 31, 2023 | 314.72 Mn |
| Dec 31, 2022 | 358.17 Mn |
| Sep 30, 2022 | 390.30 Mn |
| Jun 30, 2022 | 424.13 Mn |
| Mar 31, 2022 | 265.98 Mn |
| Dec 31, 2021 | 304.45 Mn |
| Sep 30, 2021 | 298.39 Mn |